neuro-immunology group
The Neuro-Immunology Group seeks to elucidate the complex interactions between the nervous and immune systems under tumorigenic, inflammatory or neurodegenerative conditions to identify targets to modulate neuroinflammation for specific neurological diseases.
ACTIVITIES
Inappropriate CNS immune cell reactions often underpin neurological illnesses. Thus, their underlying cellular and molecular mechanisms have emerged as a potential therapeutic target. The Neuro-Immunology Group aims to identify the immunological properties of CNS immune cells, with microglia representing the key effector cells, as well as to investigate their crosstalk with peripheral immune cells under tumorigenic, inflammatory and neurodegenerative conditions in order to identify specific programs which could represent targets for therapeutic intervention.
The group consistently achieves these goals through three steps:
1. Characterise cells at the -omics level, for instance elucidating their epigenetic, transcriptional and metabolic signatures;
2. Identify genes and pathways that are perturbed under disease conditions and compare them to homeostatic states;
3. Investigate how manipulating the identified pathways affects the acquired phenotype and eventually the disease outcome.
To reach these objectives, the group takes advantage of valuable biological samples from patients and specific mouse models for human brain tumours and neurodegenerative diseases as well as in vitro eukaryotic cell cultures. They combine -omics analyses with specific molecular biology tools and cutting-edge biochemical assays. Additionally, they work in close collaboration with bioinformaticians and computational biologists to infer the underlying networks as well as to integrate their data with existing information gathered through literature review.
On top of this systems approach, much of their attention is focused on IRG1/ACOD1, a key immune response gene expressed by myeloid cells under inflammatory, tumorigenic and neurodegenerative conditions. They have previously elucidated the function of IRG1/ACOD1 protein by demonstrating that it links metabolism to immunity by catalysing the production of the anti-microbial/anti-inflammatory metabolite itaconate from cis-aconitate in the tricarboxylic acid (TCA) cycle. Notably, their discovery contributed to pave the way to the emerging field of immunometabolism, which is currently revealing the crucial role of metabolic reprogramming in immune responses.
A better understanding of the cellular and molecular mechanisms underlying the immunological properties of CNS immune cells and the subsequent ability to manipulate them, such as render them anti-tumorigenic or neuroprotective, will pave the way to novel therapeutic applications tailored to specific neurological diseases with an immunological component.
Michelucci
Partners & Funding
Projects & clinical trials
Some of the group’s research projects include:
- Explore the local and systemic heterogeneity of myeloid cells for precision immunotherapy in glioblastoma
- Identify and harness targets to revert glioblastoma-associated immunosuppression via functional modulation of myeloid cells
- Analyse microglial responses and heterogeneity under inflammatory conditions and in Parkinson’s disease
Featured team members
-
Amandine
Bernard Laboratory Technician -
Eleonora
Campus PhD Student -
Melike
Gezen Postdoctoral Fellow -
Frida
Lind-Holm PhD Student -
Beatrice
Melin Visiting Researcher -
Alessandro
Michelucci Group Leader -
Aurélie
Poli Scientist -
Andrea
Scafidi PhD Student
Scientific publications
-
Protocol for immunofluorescence staining and large-scale analysis to quantify microglial cell morphology at single-cell resolution in mice – 04/12/2024
-
Multiomics approaches disclose very-early molecular and cellular switches during insect-venom allergen-specific immunotherapy – 26/11/2024
-
Adenoviral delivery of the CIITA transgene induces T-cell-mediated killing in glioblastoma organoids – 13/11/2024
-
Metformin impacts the differentiation of mouse bone marrow cells into macrophages affecting tumour immunity – 30/09/2024
-
Granulocytes and mast cells in AllergoOncology—Bridging allergy to cancer – 22/07/2024
-
PARK7/DJ-1 deficiency impairs microglial activation in response to LPS-induced inflammation – 16/07/2024
-
AllergoOncology – 01/01/2024
-
Glioblastoma-instructed microglia transition to heterogeneous phenotypic states with phagocytic and dendritic cell-like features in patient tumors and patient-derived orthotopic xenografts – 02/04/2024
-
Targeting the ACOD1-itaconate axis stabilizes atherosclerotic plaques – 01/04/2024
-
Multiomics approaches disclose very-early molecular and cellular switches during insect-venom allergen-specific immunotherapy – 22/02/2024
Related News
Forthcoming events
Job vacancies
-
Post-Doctoral Fellow in Brain Tumor Immunology (JA/PD1124/AP/NIG)
Department of Cancer Research – Neuro-Immunology Group